About Inverse psoriasis
Psoriasis is an immune-mediated, inflammatory condition of the skin affecting nearly 3 % of the world’s population. As a chronic disease, psoriasis has a substantial effect on the quality of life of patients. Inverse psoriasis (in skin folds) is one of several types of psoriasis that is particular sensitive to therapy.
Aim of MC2-11
Inverse psoriasis affects the skin inside the folds of the body. The skin in these areas is more sensitive, so the condition can be a challenge to manage and treat. Steroids are not suitable.
Tacrolimus ointment is recommended for and often used off-label as therapy for such areas. However, in addition to not having the appropriate label, the current marketed formulations of tacrolimus (Protopic 0.1% and 0.03%) are greasy ointments that patients do not like to use, resulting in non-compliance and poor real-life efficacy.
Using PAD™ Technology we aim to make a PAD™ cream based tacrolimus drug labelled for treatment of mild to moderate psoriasis including inverse psoriasis.
MC2-11 PAD™ Cream quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines. A solution intended to significantly improve daily quality of life of patients and provide a unique value proposition to payers, physicians and patients.
Pre-clinical – in preparation for phase 2a dose-finding study.
MC2-11 PAD™ Cream
Active ingredient: Tacrolimus
Indication: Mild to moderate psoriasis, including inverse psoriasis.